A Prospective Randomized Study of Chop Versus Chop Plus Alpha-2B Interferon in Patients with Intermediate and High Grade Non-Hodgkin's Lymphoma: The International Oncology Study Group NHL1 Study

The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL. Background: The CHOP (Cyclophosphamide, Adriamyc...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2000-12, Vol.40 (1-2), p.95-103
Main Authors: Giles, Francis J., Shan, Jianqin, Advani, Suresh H., Akan, Hamdi, Aziz, Zeba, Azim, Hamdy A., Bapsy, P. P., Buyukkececi, Filiz, Chaimongkol, Boonsoom, Cheong, Soon-Keng, Hamza, Reda, Khalid, Hussein M., Intragumtornchai, Tanin, Kim, Sang W., Kim, Sam Y., Koc, Haluk, Kumar, Lalit, Kumar, Ravi, Lei, Kenny I., Lekhakula, Arnuparp, Muthalib, Abdul, Patel, Moosa, Poovalingam, Viz P., Prayoonwiwat, Wichai, Rana, Fauzia, Reksodiputro, Arryanto H., Ruff, Paul, Sagar, T. G., Schwarera, Andrew P., Suharti, Catherine, Supindiman, Iman, Tee, Goh Y., Thamprasit, Taratorn, Villalon, Antonio H., Wickham, Nicholas R., Wong, John E., Yalcin, Attila
Format: Article
Language:English
Subjects:
a-Interferon
Adriamycin
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - toxicity
CHOP
CHOP+alpha-2b interferon
Cyclophosphamide
Cyclophosphamide - administration & dosage
Cyclophosphamide - toxicity
Doxorubicin - administration & dosage
Doxorubicin - toxicity
Female
high grade lymphomas
Humans
Interferon
Interferon alpha-2
Interferon-alpha - administration & dosage
Interferon-alpha - toxicity
Intermediate
International oncology study group
Large cell Lymphoma
Lymphoma, Non-Hodgkin - complications
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - mortality
Male
Middle Aged
non hodg-kin's lymphoma
Prednisone
Prednisone - administration & dosage
Prednisone - toxicity
Prospective Studies
Recombinant Proteins
Response
Survival
Survival Rate
Treatment Outcome
Vincristine
Vincristine - administration & dosage
Vincristine - toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL. Background: The CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) regimen is the most widely used first-line therapy for patients with Intermediate or High Grade (IG/HG) non-Hodgkin's lymphoma (NHL). Alpha 2b interferon (INF) enhances response rates and improves survival in low-grade NHL. The International Oncology Study Group (IOSG) conducted a prospective randomized study comparing CHOP alone or combined with INF in patients with IG/HG-NHL. The primary study aim was to compare the objective response rates in these patient cohorts. Patients and Methods: Patients with a confirmed diagnosis of measurable NHL of International Working Formulation (IWF) groups D to H histology were randomized to receive CHOP alone or CHOP with 5Mu INF SC for 5 days on days 22 to 26 of each 28 day cycle with INF 5 million units (Mu) given three times per week sub-cutaneously for 52 weeks in those patients who responded to CHOP plus INF. Results: The overall response rates were equivalent in both groups: CHOP alone (214 patients) 81% (complete 55%, partial 26%); CHOP plus INF (221 patients) 80% (complete 54%, partial 26%). At 36 months, the actuarial survival rate was equivalent in both groups. Conclusions: There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HG-NHL.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428190009054885